ArticleBMC infectious diseases2026
Unmasking Mycobacterium avium: two case reports of cutaneous lesions in HIV patients after initiation of an integrase inhibitor-based regimen.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMycobacterium avium complex (MAC) is the most common non-tuberculous mycobacteria (NTM) causing disease in immunosuppressed patients. People living with human immunodeficiency virus (PLHIV) typically present with disseminated infections characterized by non-specific constitutional symptoms such as fever, night sweats, and weight loss. Cutaneous lesions in disseminated MAC are rare and include panniculitis, granulomas, pustules, papules, nodules, abscesses and ulcerations, and ulcers. Here, we present two HIV patients who developed a disseminated MAC infection with skin lesions. CASE PRESENTATION: A 40-year-old woman with a 10-year history of untreated HIV infection and a 47-year-old woman recently diagnosed with HIV both presented with constitutional symptoms. After routine screening for opportunistic infections and exclusion of active infection, they were started on antiretroviral therapy (ART) with tenofovir, lamivudine, and dolutegravir. One month later, both presented inflammatory skin lesions that evolved into ulcers. Case 1 presented with painful nodules of variable size on the upper and lower extremities that subsequently suppurated and ulcerated. Case 2 presented with erythematous-violaceous nodules on the trunk and limbs that progressed to ulceration with irregular borders, well defined, infiltrated, with necrotic background and fine perilesional desquamation. The secretion of the lesions was analyzed in both cases. Ziehl-Neelsen stain showed the presence of acid-fast bacilli only in case 1, while the GeneXpert MTB/RIF assay was negative in both cases. The biopsy of case 2 documented panniculitis. Non-pigmented colony growth was observed after 42 and 38 days of incubation, respectively. PCR restriction enzyme pattern analysis demonstrated the presence of MAC in both cases. Clarithromycin and ethambutol were started in both cases, and clofazimine was added in case 1, resulting in a satisfactory clinical course in both patients, as evidenced by the healing of the ulcers.
conclusionsThese cases of disseminated MAC infection highlight that unmasking immune reconstitution inflammatory syndrome can present with severe cutaneous lesions shortly after the initiation of modern ART. Our report underscores the need for a high index of suspicion for NTM infections in patients with advanced HIV who develop new inflammatory syndromes, particularly in resource-limited settings where diagnostic delays for mycobacterial diseases are common.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.